A far shorter, simpler, and less toxic treatment protocol for patients with triple-negative breast cancer produced outcomes ...
Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.
Verywell Health on MSN7h
Navigating Care Through Every Phase of Metastatic Breast CancerIf you have metastatic breast cancer, you may need help from loved ones and your medical team along the way. Here’s how to ...
After living with metastatic breast cancer for 11 years, I reflect on my journey and plan to embrace the coming year with ...
Katrina Cooke and Ashley Dostefano share their personal journeys, reflecting on the challenges they faced, the victories they ...
T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer.
The Barbara Ann Karmanos Cancer Institute has opened the Karmanos Cancer Institute — Dearborn along Hubbard Drive, just west ...
News Medical on MSN4h
Study highlights delayed cancer diagnoses in pregnant womenCancer symptoms can sometimes be misdiagnosed as normal pregnancy-related changes for women who are expecting, in some cases leading to a delay in treatment, according to a new study from the ...
Recent advances in immunotherapy have revolutionized the treatment of breast and gynecological cancers, and current ...
The women, who range in age from 44 to 73, said they were grateful to the NHS medics who helped rid them of cancer. But many ...
SEATTLE - Atossa Therapeutics, Inc. (NASDAQ:ATOS), a biopharmaceutical company focusing on breast cancer treatment with a market capitalization of $107 million, has encountered a challenge in its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback